CLINICAL TRIALS PROFILE FOR LY3871801
✉ Email this page to a colleague
Clinical Trials for LY3871801
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT05222399 ↗ | A Study of LY3871801 in Healthy Participants | Not yet recruiting | Eli Lilly and Company | Phase 1 | The main purpose of this study is to compare the amount of LY3871801 that gets into the blood stream and how long it takes the body to get rid of it, when given as crystalline freebase tablet (test) and as a solid dispersion oral suspension (reference) in healthy participants. The information about any adverse effects experienced will be collected and the tolerability of LY3871801 will also be evaluated. The study may last up to approximately 15 days excluding the 28 days of screening period. |
| NCT05602675 ↗ | A Drug Interaction Study of LY3871801 in Healthy Participants | Not yet recruiting | Eli Lilly and Company | Phase 1 | The main purpose of this study is to determine the effect of LY3871801 when administered orally on the levels of methotrexate (part 1), drug cocktail (warfarin, dextromethorphan, and midazolam) and repaglinide (part 2) in the blood stream when administered orally in healthy participants. The information about any adverse effects experienced will be collected and the tolerability of LY3871801 will also be evaluated. The study may last up to approximately 25 days for each participant. |
| NCT05848258 ↗ | An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis | Not yet recruiting | Rigel Pharmaceuticals | Phase 2 | The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA). |
| NCT05848258 ↗ | An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis | Not yet recruiting | Eli Lilly and Company | Phase 2 | The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA). |
| NCT05960851 ↗ | A Study of LY3871801 in Healthy Asian and Non-Asian Participants | Completed | Eli Lilly and Company | Phase 1 | The main purpose of this study is to evaluate the safety and tolerability of LY3871801 when administered as multiple doses in Healthy Asian and Non-Asian Participants. The study will also evaluate the amount of LY3871801 that gets into the blood stream and how long it takes the body to get rid of it in these participants. The study will be conducted in two parts (A & B). The study will last up to approximately 24 days excluding the screening period. |
| NCT06049108 ↗ | A Study of Carbon-14-Labelled [14C] LY3871801 in Healthy Male Participants | Completed | Eli Lilly and Company | Phase 1 | The main purpose of this study is to evaluate how much of the study drug (LY3871801), administered as a single dose that has the radioactive substance 14C incorporated into it, passes from blood into urine, feces and expired air in healthy male participants. The study will also measure how much of the study drug gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study will last up to approximately 9 weeks including the screening period. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for LY3871801
Condition Name
Clinical Trial Locations for LY3871801
Trials by Country
Clinical Trial Progress for LY3871801
Clinical Trial Phase
Clinical Trial Sponsors for LY3871801
Sponsor Name
